# Proposed Rule Would Allow Expansion of Cannabis Research in Missouri > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/missouri-cannabis-research-expansion-new-facilities/ > **Published:** 2026-04-13T12:25:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:23:21-04:00 > **Clinical Summary:** Missouri cannabis research expansion proposed rule could enable new facilities to advance clinical research on cannabis efficacy and safety. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustry Why This Matters This proposed rule could expand the evidence base for cannabis efficacy and safety by enabling more rigorous [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on human subjects, which currently remains severely limited by federal restrictions. Clinicians caring for patients interested in or using cannabis would benefit from better quality evidence to inform dosing recommendations, drug interactions, and appropriate medical applications rather than relying on anecdotal reports. Increased research infrastructure in Missouri may also accelerate identification of specific cannabis-derived compounds suitable for clinical development and FDA approval pathways. Clinical Summary Missouri’s proposed rule would establish a regulatory framework enabling multiple entities to conduct [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), including studies involving human subjects, potentially expanding the evidence base for cannabis therapeutics in clinical practice. This policy development is significant because it removes numerical restrictions on research facilities, which could accelerate investigation into cannabis efficacy, safety profiles, and optimal dosing strategies across various medical conditions. For clinicians currently prescribing cannabis in Missouri or considering its use, expanded research infrastructure may provide better quality evidence to guide patient selection and treatment protocols. The regulatory pathway outlined in the proposal could facilitate both preclinical research on cannabis plant constituents and human clinical trials that have been limited by federal scheduling and previous state restrictions. As evidence accumulates through these sanctioned research programs, clinicians will have access to peer-reviewed data to support informed discussions with patients about potential benefits and risks. Clinicians should monitor this regulatory development, as approval of such facilities could improve the evidence quality available for cannabis-related clinical decision making in their practices. Dr. Caplan’s Take “If Missouri removes the artificial constraints on cannabis research facilities, we’ll finally have the domestic infrastructure to answer the clinical questions my patients are actually asking me today, rather than continuing to rely on outdated federal scheduling that treats cannabis like it has no medical applications whatsoever.” Clinical Perspective Missouri’s proposed expansion of cannabis research facilities could increase the quantity and diversity of evidence available to inform clinical decision-making around cannabinoid therapeutics, particularly regarding dosing, formulation, and safety profiles that remain inadequately characterized in the current literature. However, clinicians should remain cautious about the timeline for translating facility-level research into clinically actionable guidance, as the regulatory pathway from bench research to FDA-approved therapeutics or clinical guidelines is lengthy and subject to federal constraints that may limit data sharing or interstate collaboration. Additionally, without clear quality standards, institutional oversight mechanisms, and publication requirements embedded in the proposal, there is risk that research findings may be fragmented, duplicative, or difficult to synthesize into coherent clinical recommendations. Until such facilities generate rigorous, peer-reviewed evidence, practitioners should continue relying on existing literature and may consider engaging with institutional review boards to thoughtfully evaluate off-label or investigational cannabinoid use in appropriate 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Proposed+rule+would+allow+for+creation+of+marijuana+research+facilities+in+Missouri+%40drcaplan&url=https%3A%2F%2Fwww.missourinet.com%2F2026%2F04%2F13%2Fproposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.missourinet.com%2F2026%2F04%2F13%2Fproposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Proposed+rule+would+allow+for+creation+of+marijuana+research+facilities+in+Missouri+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.missourinet.com%2F2026%2F04%2F13%2Fproposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [North Carolina Governor Endorses Adult-Use Cannabis Market Proposed by Council](https://cedclinic.com/north-carolina-cannabis-policy-changes-adult-use-market/) - [Mass Senate proposes $1M for cannabis awareness campaign – WCVB](https://cedclinic.com/massachusetts-cannabis-awareness-campaign-funding/) - [Effort to allow more employers to fire medical marijuana users – YouTube](https://cedclinic.com/employment-protections-medical-cannabis-users-workplace-policy/) 📰 Source: [https://www.missourinet.com/2026/04/13/proposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri/](https://www.missourinet.com/2026/04/13/proposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri/) Further Reading CED Clinic Blog[Semaglutide vs Tirzepatide Comparison: Which Works Better and Why](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Research Digest[Research Digest: 4 Recent Studies – April 09, 2026](https://cedclinic.com/4-recent-cannabis-research-studies-april-2026/) Cannabis Policy Wire[Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I](https://cedclinic.com/4-fluoroamphetamine-schedule-i-placement/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump administration reclassifies cannabis in major shift that could expand scientific research – MSN](https://cedclinic.com/federal-cannabis-reclassification-medical-research/) Explore how federal cannabis reclassification under the Trump administration could broaden scientific research opportunities nationwide. [Read More](https://cedclinic.com/federal-cannabis-reclassification-medical-research/) [Trump Administration to reclassify medical marijuana restrictions, expanding research potential](https://cedclinic.com/trump-administration-cannabis-research-expansion/) Learn about federal efforts to ease [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) restrictions and their impact on expanding research potential. [Discover More](https://cedclinic.com/trump-administration-cannabis-research-expansion/) [Reps. Dina Titus and Ilhan Omar Introduce Higher Education Marijuana Research Act](https://cedclinic.com/academic-cannabis-research-funding-gap-act/) Understand legislative initiatives aimed at supporting marijuana research through higher education institutions. [Explore Act](https://cedclinic.com/academic-cannabis-research-funding-gap-act/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).